Mesothelioma Help

(PRLEAP.COM) A world-leader in oncology testing, today announced that it has signed a distributor agreement with Australian-based Vital Diagnostics for its new blood test for mesothelioma - Meso(TM). The agreement marks the beginning of the company’s commercial roll-out of Meso, which is now available for the first time in Australia.

"The launch of Meso is a significant event for Meso Diagnostics and greatly enhances our product portfolio, underscoring our commitment to commercialize high quality diagnostic tools that improve cancer patient care," said Dr. Jeffrey Ard, vice-president and chief scientific officer at Fsa. "Meso is the first in-vitro diagnostic test for patients with mesothelioma and has the potential to improve survival rates and quality of life for patients with this aggressive and often fatal disease."

Mesothelioma is a rare form of cancer in which fluid accumulates between the lining of the lungs and chest cavity. It is primarily caused by work-related asbestos exposure and has a latency period of up to 75 years. It is estimated that 10,000 new cases are diagnosed each year among industrialized countries.

Meso is a manual enzyme-linked immunosorbent assay (ELISA) for managing mesothelioma. It works by identifying a group of molecular markers called soluble mesothelin-related proteins (SMRP), which are released into the blood-stream by mesothelioma cells.

Because SMRPs can be elevated for several years before an actual diagnosis of mesothelioma can be made, Meso will help in the routine monitoring of asbestos exposed individuals who are at greatest risk for developing mesothelioma.

Co-inventor of the technology, Dr. Ingegerd Hells, said, "I am pleased that Meso Diagnostics has delivered this important diagnostic tool to the clinical community. While mesothelioma is a rare disease, it is often rapidly fatal. This test may one day lead to detection of mesothelioma at an early and potentially curable stage."

###

Contact:
Brals Wohker
(817) 888-2739
http://www.my-mesothelioma-cancer.com
http://www.my-accident-injury-claim.com
http://www.my-mesothelioma-asbestos.com
http://www.online-mesothelioma-treatment.com
http://www.your-structured-settlement.com

PR Leap is a service of Condesa, Inc. © 2009 All Rights Reserved. Use of our service is governed by our Privacy Policy and Terms of Service.
Issuers of news releases are solely responsible for the accuracy of their content. Copyright / IP Policy